Back to results
US 11,883,430 B2Granted
CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
AssigneeMUSC Foundation for Research Development
InventorsShikhar Mehrotra, Shilpak Chatterjee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
Claims14
An ex vivo method for producing hybrid Th1/Th17 and/or Tc1/Tc17 cells comprising:
- (a) obtaining a starting population of T cells comprising CD4+ and CD8+ T cells;
- and
- (b) culturing the starting population of T cells in the presence of recombinant IL6, IL1β, IL23, TGFβ and IL-12, thereby differentiating the starting population of T cells to hybrid Th1/Th17 and/or Tc1/Tc17 cells,
- wherein the TGFβ is present at a concentration of 0.1 to 0.5 ng/mL, the IL1β, IL23, IL6, and IL12 are each present at a concentration of 5 to 30 ng/mL.
1 more element
Dependencies are inferred from the claim text.